339 related articles for article (PubMed ID: 33926539)
1. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial.
Walma MS; Rombouts SJ; Brada LJH; Borel Rinkes IH; Bosscha K; Bruijnen RC; Busch OR; Creemers GJ; Daams F; van Dam RM; van Delden OM; Festen S; Ghorbani P; de Groot DJ; de Groot JWB; Haj Mohammad N; van Hillegersberg R; de Hingh IH; D'Hondt M; Kerver ED; van Leeuwen MS; Liem MS; van Lienden KP; Los M; de Meijer VE; Meijerink MR; Mekenkamp LJ; Nio CY; Oulad Abdennabi I; Pando E; Patijn GA; Polée MB; Pruijt JF; Roeyen G; Ropela JA; Stommel MWJ; de Vos-Geelen J; de Vries JJ; van der Waal EM; Wessels FJ; Wilmink JW; van Santvoort HC; Besselink MG; Molenaar IQ;
Trials; 2021 Apr; 22(1):313. PubMed ID: 33926539
[TBL] [Abstract][Full Text] [Related]
2. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
Shimomura O; Endo M; Makishima H; Yamada T; Hashimoto S; Numajiri H; Miyazaki Y; Doi M; Furuya K; Takahashi K; Moriwaki T; Hasegawa N; Yamamoto Y; Niisato Y; Kobayashi M; Mizumoto M; Nakai K; Saito T; Hoshiai S; Saida T; Mathis BJ; Mori K; Nakajima T; Tsuchiya K; Sakurai H; Oda T
BMC Cancer; 2023 Jul; 23(1):624. PubMed ID: 37403011
[TBL] [Abstract][Full Text] [Related]
3. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation.
He C; Wang J; Zhang Y; Cai Z; Lin X; Li S
Cancer Med; 2020 Jul; 9(13):4699-4710. PubMed ID: 32410380
[TBL] [Abstract][Full Text] [Related]
4. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial.
Frigerio I; Paiella S; Barbi E; Bianco R; Boz G; Butturini G; Cantore M; Cardarelli N; Mirko D; Fiorentini G; Giardino A; Lionetto G; Malleo G; Mambrini A; Milella M; Passardi A; Regi P; Salvia R; Scopelliti F; Viviani E; Bassi C; Girelli R
Pancreatology; 2021 Oct; 21(7):1342-1348. PubMed ID: 34215498
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).
Rasmussen LS; Winther SB; Chen IM; Weber B; Ventzel L; Liposits G; Johansen JS; Detlefsen S; Egendal I; Shim S; Christensen S; Pfeiffer P; Ladekarl M
BMC Cancer; 2023 Jun; 23(1):552. PubMed ID: 37328835
[TBL] [Abstract][Full Text] [Related]
6. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols.
Narayanan G; Bilimoria MM; Hosein PJ; Su Z; Mortimer KM; Martin RCG
BMC Cancer; 2021 Jul; 21(1):785. PubMed ID: 34233640
[TBL] [Abstract][Full Text] [Related]
7. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).
Hartlapp I; Valta-Seufzer D; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens UM; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Anger F; Germer CT; Stang A; Kimmel B; Heinemann V; Kunzmann V;
ESMO Open; 2022 Aug; 7(4):100552. PubMed ID: 35970013
[TBL] [Abstract][Full Text] [Related]
9. Safety of radiofrequency ablation in patients with locally advanced, unresectable pancreatic cancer: A phase II study.
Fegrachi S; Walma MS; de Vries JJJ; van Santvoort HC; Besselink MG; von Asmuth EG; van Leeuwen MS; Borel Rinkes IH; Bruijnen RC; de Hingh IH; Klaase JM; Molenaar IQ; van Hillegersberg R
Eur J Surg Oncol; 2019 Nov; 45(11):2166-2172. PubMed ID: 31227340
[TBL] [Abstract][Full Text] [Related]
10. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy.
Stoop TF; Seelen LWF; van 't Land FR; Lutchman KRD; van Dieren S; Lips DJ; van der Harst E; Kazemier G; Patijn GA; de Hingh IH; Wijsman JH; Erdmann JI; Festen S; Groot Koerkamp B; Mieog JSD; den Dulk M; Stommel MWJ; Busch OR; de Wilde RF; de Meijer VE; Te Riele W; Molenaar IQ; van Eijck CHJ; van Santvoort HC; Besselink MG;
Ann Surg Oncol; 2024 Apr; 31(4):2640-2653. PubMed ID: 38105377
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for pancreatic cancer.
Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence.
Seufferlein T; Hammel P; Delpero JR; Macarulla T; Pfeiffer P; Prager GW; Reni M; Falconi M; Philip PA; Van Cutsem E
Cancer Treat Rev; 2019 Jul; 77():1-10. PubMed ID: 31163334
[TBL] [Abstract][Full Text] [Related]
13. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
Buisman FE; Homs MYV; Grünhagen DJ; Filipe WF; Bennink RJ; Besselink MGH; Borel Rinkes IHM; Bruijnen RCG; Cercek A; D'Angelica MI; van Delden OM; Donswijk ML; van Doorn L; Doornebosch PG; Emmering J; Erdmann JI; IJzerman NS; Grootscholten C; Hagendoorn J; Kemeny NE; Kingham TP; Klompenhouwer EG; Kok NFM; Koolen S; Kuhlmann KFD; Kuiper MC; Lam MGE; Mathijssen RHJ; Moelker A; Oomen-de Hoop E; Punt CJA; Te Riele WW; Roodhart JML; Swijnenburg RJ; Prevoo W; Tanis PJ; Vermaas M; Versleijen MWJ; Veuger FP; Weterman MJ; Verhoef C; Groot Koerkamp B
BMC Cancer; 2019 Apr; 19(1):327. PubMed ID: 30953467
[TBL] [Abstract][Full Text] [Related]
15. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.
Hill CS; Rosati L; Wang H; Tsai HL; He J; Hacker-Prietz A; Laheru DA; Zheng L; Sehgal S; Bernard V; Le DT; Pawlik TM; Weiss MJ; Narang AK; Herman JM
Pract Radiat Oncol; 2022; 12(6):511-523. PubMed ID: 35306231
[TBL] [Abstract][Full Text] [Related]
16. Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-PIE) trial: study protocol for a feasibility randomised controlled trial.
Rai ZL; Ranieri V; Palmer DH; Littler P; Ghaneh P; Gurusamy K; Manas D; Pizzo E; Psarelli EE; Gilmore R; Peddu P; Bartlett DC; de Liguori Carino N; Davidson BR
BMJ Open; 2022 May; 12(5):e050166. PubMed ID: 35551086
[TBL] [Abstract][Full Text] [Related]
17. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
18. Study protocol for a multicenter randomized controlled trial to compare radiofrequency ablation with surgical resection for treatment of pancreatic insulinoma.
Crinò SF; Partelli S; Napoleon B; Conti Bellocchi MC; Facciorusso A; Salvia R; Forti E; Cintolo M; Mazzola M; Ferrari G; Carrara S; Repici A; Zerbi A; Lania A; Tacelli M; Arcidiacono PG; Falconi M; Larghi A; Rizzatti G; Alfieri S; Panzuto F; Hindryckx P; Berrevoet F; Lapauw B; Lakhtakia S; Sundaram S; Samanta J; Rastogi A; Landoni L
Dig Liver Dis; 2023 Sep; 55(9):1187-1193. PubMed ID: 37407318
[TBL] [Abstract][Full Text] [Related]
19. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
20. Computed tomography findings after radiofrequency ablation in locally advanced pancreatic cancer.
Rombouts SJE; Derksen TC; Nio CY; van Hillegersberg R; van Santvoort HC; Walma MS; Molenaar IQ; van Leeuwen MS
Abdom Radiol (NY); 2018 Oct; 43(10):2702-2711. PubMed ID: 29492602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
